SAN FRANCISCO, CA--(Marketwire - Jan 31, 2013) - Foresite Capital Management, LLC, a growth equity firm founded by Jim Tananbaum to finance late-stage healthcare companies, today announced the close of its $100 million fund, Foresite Capital Fund I. The firm draws on Tananbaum and his partners' deep experience and expertise in building leading healthcare companies, as well as their broad private and public investment experience.
"We are marrying the best practices of growth investing with healthcare specialization," said Jim Tananbaum, founder and managing director of Foresite Capital Management. "We are proud of our capital base, extremely excited about the prospects for healthcare growth, and believe on a risk-adjusted basis there has never been a better time to have this focus."
Foresite Capital invests in companies with disruptive, late-stage products and services in a broad range of healthcare from biotechnology, genomics and diagnostics to healthcare services and medical devices. Current portfolio companies include AcelRx Pharmaceuticals (
About Foresite Capital Management
Foresite Capital Management was founded in 2011 by veteran healthcare investor Jim Tananbaum based on his vision to build a firm focused on providing growth capital to healthcare companies with disruptive late-stage products or services. Foresite Capital consists of five partners based in San Francisco and New York. The team has a diverse set of healthcare expertise, deep experience in private and public healthcare investing, and a strong track record of building companies and delivering investor returns. During the last two decades Foresite Capital's partners have led financings that produced five multi-billion dollar outcomes. The team's experience also includes leadership positions in operations, clinical, marketing, business development, communications, and finance. Foresite Capital is based in San Francisco, California with an office in Manhattan, New York.